Cellectar shareholders back share plan increase and warrant exercise vote
At its July 7, 2026 annual meeting, Cellectar Biosciences investors approved a 2,000,000-share increase to the equity incentive plan and a proposal allowing exercise of warrants for up to 39.6 million shares.
Cellectar Biosciences, Inc. held its 2026 Annual Meeting of Stockholders on July 7, 2026, according to an 8-K filed with the SEC. The Company held the Annual Meeting at 10:00 a.m., local time, on July 7, 2026.1
Shareholders reelected two Class III directors. Andrew Gu and Douglas J. Swirsky were nominated and elected to serve three-year terms.1
Investors also approved an amendment expanding the company's equity plan. Stockholders approved an amendment to the Company's 2021 Stock Incentive Plan to increase the number of shares reserved for issuance under the Plan by 2,000,000 shares.1
On the audit front, shareholders backed keeping Deloitte & Touche LLP as the company's outside auditor. The company had asked stockholders to ratify the Audit Committee's appointment of Deloitte & Touche LLP as its independent registered public accounting firm for fiscal year 2026, and the appointment was ratified.1
Shareholders approved, on an advisory basis, the pay packages given to named executive officers. The proposal covered non-binding approval of named executive officer compensation, and stockholders approved it.1
A separate proposal dealt with warrants the company had issued. The company sought approval to allow holders to exercise warrants for up to 39,618,078 shares of common stock, under Nasdaq Stock Market rules, and stockholders approved this warrant exercise proposal.1 Because that vote passed, a separate agenda item to adjourn the meeting was no longer needed and was not brought up.1
The 8-K was signed by Chief Financial Officer Chad J. Kolean and dated July 10, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.